Thyroid transcription factor-1 expression in lung neuroendocrine tumours: a gender-related biomarker?

Biomarkers Gender medicine Lung neuroendocrine tumours Thyroid transcription factor‐1 (TTF-1)

Journal

Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444

Informations de publication

Date de publication:
30 Sep 2023
Historique:
received: 27 07 2023
accepted: 15 09 2023
medline: 30 9 2023
pubmed: 30 9 2023
entrez: 29 9 2023
Statut: aheadofprint

Résumé

Thyroid transcription factor-1 (TTF-1) assessed by immunohistochemistry (IHC) is a specific biomarker for lung adenocarcinoma, and is commonly used to confirm the pulmonary origin of neuroendocrine tumours (NET). The majority of the available data suggest that TTF-1 is favourable prognostic biomarker for lung adenocarcinomas, whereas its role is more conflicting for lung NET. The main aim of this multicenter retrospective study was to investigate the potentially relevant associations between TTF-1 biomarker and clinical and pathological features of the study population, as well as determine TTF-1 prognostic effect on the clinical outcome of the patients. A multicentre retrospective study was conducted on 155 surgically-removed lung NET, with available IHC TTF-1 assessment. Median age was 59.5 years (range 13-86), 97 patients (62.6%) were females, 31 cases (20%) were atypical carcinoids, 4 (2.6%) had TNM stage IV. Mitotic count ≥2 per 10 high-power field was found in 35 (22.6%) subjects, whereas necrosis was detected in 20 patients (12.9%). TTF-1 was positive in 78 cases (50.3%). The median overall survival was 46.9 months (range 0.6-323) and the median progression-free survival was 39.1 months (range 0.6-323). Statistically significant associations were found between (1) TTF-1 positivity and female sex (p = 0.007); and among (2) TTF-1 positivity and the absence of necrosis (p = 0.018). This study highlights that TTF-1 positivity differs according to sex in lung NET, with a more common TTF-1 positive staining in female. Moreover, TTF-1 positivity correlated with the absence of necrosis. These data suggest that TTF-1 could potentially represent a gender-related biomarker for lung NET.

Identifiants

DOI: 10.1007/s12020-023-03542-0 PMID: 37775725
pubmed: 37775725
doi: 10.1007/s12020-023-03542-0
pii: 10.1007/s12020-023-03542-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2023. The Author(s).

Références

K. Ikeda, J.C. Clark, J.R. Shaw-White, M.T. Stahlman, C.J. Boutell, J.A. Whitsett, Gene structure and expression of human thyroid transcription factor‐1 in respiratory epithelial cells. J. Biol. Chem. 270, 8108–8114 (1995)
doi: 10.1074/jbc.270.14.8108 pubmed: 7713914
L. Guan, X. Zhao, L. Tang, J. Chen, J. Zhao, M. Guo et al. Thyroid transcription factor-1: structure, expression, function and its relationship with disease. Biomed. Res. Int. 2021, 9957209 (2021). https://doi.org/10.1155/2021/9957209
doi: 10.1155/2021/9957209 pubmed: 34631891 pmcid: 8494563
S. Kimura, Y. Hara, T. Pineau, P. Fernandez-Salguero, C.H. Fox, J.M. Ward et al. The T/ebp null mouse: thyroid‐specific enhancer‐binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes Dev. 10, 60–69 (1996)
doi: 10.1101/gad.10.1.60 pubmed: 8557195
O. Kaufmann, M. Dietel, Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology 36, 8–16 (2000). https://doi.org/10.1046/j.1365-2559.2000.00801.x
doi: 10.1046/j.1365-2559.2000.00801.x pubmed: 10632746
E.Z. Du, P. Goldstraw, J. Zacharias, O. Tiffet, P.J. Craig, A.G. Nicholson et al. TTF-1 expression is specific for lung primary in typical and atypical carcinoids: TTF-1-positive carcinoids are predominantly in peripheral location. Hum. Pathol. 35, 825–831 (2004). https://doi.org/10.1016/j.humpath.2004.02.016
doi: 10.1016/j.humpath.2004.02.016 pubmed: 15257545
A. Saqi, D. Alexis, F. Remotti, G. Bhagat, Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids. Am. J. Clin. Pathol. 123, 394–404 (2005). https://doi.org/10.1309/UKN6-PVRK-XHG4-22DA
doi: 10.1309/UKN6-PVRK-XHG4-22DA pubmed: 15716236
C. Zhang, L.A. Schmidt, K. Hatanaka, D. Thomas, A. Lagstein, J.L. Myers, Evaluation of napsin A, TTF-1, p63, p40, and CK5/6 immunohistochemical stains in pulmonary neuroendocrine tumours. Am. J. Clin. Pathol. 142, 320–324 (2014). https://doi.org/10.1309/AJCPGA0IUA8BHQEZ
doi: 10.1309/AJCPGA0IUA8BHQEZ pubmed: 25125621
A. Srivastava, J.L. Hornick, Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumours from pancreatic endocrine and pulmonary carcinoid tumours. Am. J. Surg. Pathol. 33, 626–632 (2009). https://doi.org/10.1097/PAS.0b013e31818d7d8b
doi: 10.1097/PAS.0b013e31818d7d8b pubmed: 19065104
N.H. Au, M. Cheang, D.G. Huntsman, E. Yorida, A. Coldman, W.M. Elliott et al. Evaluation of immunohistochemical markers in non‐small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J. Pathol. 204, 101–109 (2004)
doi: 10.1002/path.1612 pubmed: 15307143
T. Berghmans, M. Paesmans, C. Mascaux, B. Martin, A.P. Meert, A. Haller et al. Thyroid transcription factor 1—a new prognostic factor in lung cancer: a meta‐analysis. Ann. Oncol. 17, 1673–1676 (2006)
doi: 10.1093/annonc/mdl287 pubmed: 16980598
G. Centonze, P. Maisonneuve, M. Simbolo, V. Lagano, F. Grillo, A. Fabbri et al. Lung carcinoid tumours: histology and Ki-67, the eternal rivalry. Histopathology 82, 324–339 (2023). https://doi.org/10.1111/his.14819
doi: 10.1111/his.14819 pubmed: 36239545
V.E. Georgakopoulou, E. Zygouris, C. Damaskos, A. Pierrakou, P. Papalexis, N. Garmpis et al. Prognostic value of the immunohistochemistry markers CD56, TTF-1, synaptophysin, CEA, EMA and NSE in surgically resected lung carcinoid tumours. Mol. Clin. Oncol. 16, 31 (2022). https://doi.org/10.3892/mco.2021.2464
A. La Salvia, I. Persano, A. Siciliani, M. Verrico, M. Bassi, R. Modica et al. Prognostic significance of laterality in lung neuroendocrine tumours. Endocrine 76, 733–746 (2022). https://doi.org/10.1007/s12020-022-03015-w
doi: 10.1007/s12020-022-03015-w pubmed: 35301675 pmcid: 9156515
A. La Salvia, R. Carletti, M. Verrico, T. Feola, G. Puliani, M. Bassi et al. Angioside: the role of angiogenesis and hypoxia in lung neuroendocrine tumours according to primary tumour location in left or right parenchyma. J. Clin. Med. 11, 5958 (2022). https://doi.org/10.3390/jcm11195958
doi: 10.3390/jcm11195958 pubmed: 36233825 pmcid: 9570740
G. Rindi, H. Moch, W.G. McCluggage et al. Neuroendocrine neoplasms, non-endocrine organs. in WHO Classification of Tumours Endocrine and Neuroendocrine Tumours, 5th edn. ed. by WHO Classification of Tumours Editorial Board (International Agency for Research on Cancer (IARC), Lyon France, 2022).
J.B. Rubin, The spectrum of sex differences in cancer. Trends Cancer 8, 303–315 (2022). https://doi.org/10.1016/j.trecan.2022.01.013
doi: 10.1016/j.trecan.2022.01.013 pubmed: 35190302 pmcid: 8930612
A.D. Wagner, S. Oertelt-Prigione, A. Adjei, T. Buclin, V. Cristina, C. Csajka et al. Gender medicine and oncology: report and consensus of an ESMO workshop. Ann. Oncol. 30, 1914–1924 (2019). https://doi.org/10.1093/annonc/mdz414
doi: 10.1093/annonc/mdz414 pubmed: 31613312
C. Marosi, Gender aspects of treatment and drug related toxicity in medical oncology. Wien. Med. Wochenschr. 156, 534–540 (2006). https://doi.org/10.1007/s10354-006-0347-9
doi: 10.1007/s10354-006-0347-9 pubmed: 17103290
M.C.S. Wong, J. Huang, V. Lok, J. Wang, F. Fung, H. Ding, Z.J. Zheng, Differences in incidence and mortality trends of colorectal cancer worldwide based on sex, age, and anatomic location. Clin. Gastroenterol. Hepatol. 19, 955–966.e61 (2021). https://doi.org/10.1016/j.cgh.2020.02.026
doi: 10.1016/j.cgh.2020.02.026 pubmed: 32088300
H. Fajkovic, J.A. Halpern, E.K. Cha, A. Bahadori, T.F. Chromecki, P.I. Karakiewicz, E. Breinl, A.S. Merseburger, S.F. Shariat, Impact of gender on bladder cancer incidence, staging, and prognosis. World J. Urol. 29, 457–463 (2011). https://doi.org/10.1007/s00345-011-0709-9
doi: 10.1007/s00345-011-0709-9 pubmed: 21656173
G.R.C. Clark, C.G. Fraser, J.A. Strachan, R.J.C. Steele, Sex variation in colorectal cancer mortality: trends and implications for screening. Eur. J. Public Health 33, 331–335 (2023). https://doi.org/10.1093/eurpub/ckad029
doi: 10.1093/eurpub/ckad029 pubmed: 36847663 pmcid: 10066495
C. Stapelfeld, C. Dammann, E. Maser, Sex-specificity in lung cancer risk. Int. J. Cancer 146, 2376–2382 (2020). https://doi.org/10.1002/ijc.32716
doi: 10.1002/ijc.32716 pubmed: 31583690
P. Wele, X. Wu, H. Shi, Sex-dependent differences in colorectal cancer: with a focus on obesity. Cells 11, 3688 (2022). https://doi.org/10.3390/cells11223688
doi: 10.3390/cells11223688 pubmed: 36429114 pmcid: 9688265
K. Esposito, P. Chiodini, A. Colao, A. Lenzi, D. Giugliano, Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 35, 2402–2411 (2012). https://doi.org/10.2337/dc12-0336
doi: 10.2337/dc12-0336 pubmed: 23093685 pmcid: 3476894
T.J. Key, V. Beral, Sex hormones and cancer. IARC Sci. Publ. 116, 255–269 (1992)
J.H. Lin, E. Giovannucci, Sex hormones and colorectal cancer: what have we learned so far? J. Natl Cancer Inst. 102, 1746–1747 (2010). https://doi.org/10.1093/jnci/djq444
doi: 10.1093/jnci/djq444 pubmed: 21068431 pmcid: 2994865
G. Muscogiuri, L. Barrea, T. Feola, M. Gallo, E. Messina, M.A. Venneri et al. NIKE (Neuroendocrine Tumours, Innovation in Knowledge and Education) Group. Pancreatic Neuroendocrine Neoplasms: does sex matter? Trends Endocrinol. Metab. 31, 631–641 (2020). https://doi.org/10.1016/j.tem.2020.02.010
doi: 10.1016/j.tem.2020.02.010 pubmed: 32223919
J.A. Greenberg, N.A. Ivanov, C.E. Egan, Y.J. Lee, R. Zarnegar, T.J. Fahey 3rd et al. Sex-based clinicopathologic and survival differences among patients with pancreatic neuroendocrine tumours. J. Gastrointest. Surg. 26, 2321–2329 (2022). https://doi.org/10.1007/s11605-022-05345-6
doi: 10.1007/s11605-022-05345-6 pubmed: 35915373
Z. Xu, L. Wang, S. Dai, M. Chen, F. Li, J. Sun et al. Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumours in the United States. JAMA Netw. Open 4, e2124750 (2021). https://doi.org/10.1001/jamanetworkopen.2021.24750
doi: 10.1001/jamanetworkopen.2021.24750 pubmed: 34554237 pmcid: 8461504
O. Abdel-Rahman, S. Ghosh, N. Fazio, Sex-based differences in the outcomes of patients with lung carcinoids. J. Comp. Eff. Res. 11, 523–531 (2022). https://doi.org/10.2217/cer-2021-0205
doi: 10.2217/cer-2021-0205 pubmed: 35388711
C. Kesrouani, C. Ghorra, M. Rassy, H.R. Kourie, J. Kattan, Distribution and characteristics of pulmonary neuroendocrine tumors: single institution experience in Lebanon. Asian Pac. J. Cancer Prev. 17(5), 2579–2581 (2016)
pubmed: 27268633
E.Z. Du, P. Goldstraw, J. Zacharias, O. Tiffet, P.J. Craig, A.G. Nicholson, N. Weidner, E.S. Yi, TTF-1 expression is specific for lung primary in typical and atypical carcinoids: TTF-1-positive carcinoids are predominantly in peripheral location. Hum. Pathol. 35, 825–831 (2004). https://doi.org/10.1016/j.humpath.2004.02.016
doi: 10.1016/j.humpath.2004.02.016 pubmed: 15257545
X. Zeng, S.E. Wert, R. Federici, K.G. Peters, J.A. Whitsett, VEGF enhances pulmonary vasculogenesis and disrupts lung morphogenesis in vivo. Dev. Dyn. 211, 215–227 (1998). 10.1002/(SICI)1097-0177(199803)211:3<215:AID-AJA3>3.0.CO;2-K
doi: 10.1002/(SICI)1097-0177(199803)211:3<215::AID-AJA3>3.0.CO;2-K pubmed: 9520109
Y. Maeda, V. Davé, J.A. Whitsett, Transcriptional control of lung morphogenesis. Physiol. Rev. 87, 219–244 (2007). https://doi.org/10.1152/physrev.00028.2006
doi: 10.1152/physrev.00028.2006 pubmed: 17237346
L.W. Wood, N.I. Cox, C.A. Phelps, S.C. Lai, A. Poddar, C. Talbot Jr et al. Thyroid transcription factor 1 reprograms angiogenic activities of secretome. Sci. Rep. 6, 19857 (2016). https://doi.org/10.1038/srep19857
doi: 10.1038/srep19857 pubmed: 26912193 pmcid: 4766481
A. Takeuchi, T. Oguri, Y. Yamashita, K. Sone, S. Fukuda, O. Takakuwa et al. TTF-1 expression predicts the merit of additional antiangiogenic treatment in non-squamous non-small cell lung cancer. Anticancer Res. 38, 5489–5495 (2018). https://doi.org/10.21873/anticanres.12882
doi: 10.21873/anticanres.12882 pubmed: 30194207
A. Ianniello, M. Sansovini, S. Severi, S. Nicolini, C.M. Grana, K. Massri et al. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET. Eur. J. Nucl. Med. Mol. Imaging 43, 1040–1046 (2016). https://doi.org/10.1007/s00259-015-3262-8
doi: 10.1007/s00259-015-3262-8 pubmed: 26611427
T. Vesterinen, S. Mononen, K. Salmenkivi, H. Mustonen, J. Räsänen, J.A. Salo et al. Clinicopathological indicators of survival among patients with pulmonary carcinoid tumor. Acta Oncol. 57, 1109–1116 (2018). https://doi.org/10.1080/0284186X.2018.1441543
doi: 10.1080/0284186X.2018.1441543 pubmed: 29463166

Auteurs

Anna La Salvia (A)

National Center for Drug Research and Evaluation, National Institute of Health (ISS), Rome, Italy.

Alessandra Siciliani (A)

Department of Thoracic Surgery, Sant'Andrea University Hospital, Rome, Italy.

Maria Rinzivillo (M)

Digestive Disease Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Rome, Italy.

Monica Verrico (M)

Department of Radiological, Oncological, and Pathological Sciences, Sapienza University of Rome, Rome, Italy.

Roberto Baldelli (R)

Endocrinology Unit, Department of Oncology and Medical Specialities, A.O. San Camillo-Forlanini, Rome, Italy.

Giulia Puliani (G)

Oncological Endocrinology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Roberta Modica (R)

Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Isabella Zanata (I)

Department of Medical Sciences, Section of Endocrinology and Internal Medicine, University of Ferrara, Ferrara, Italy.

Irene Persano (I)

Department of Oncology, A.O.U. San Luigi Gonzaga Hospital, Orbassano, TO, Italy.

Giuseppe Fanciulli (G)

Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.
Endocrine Oncology Program, Endocrine Unit, Azienda Ospedaliero-Universitaria (AOU) Sassari, Sassari, Italy.

Massimiliano Bassi (M)

Department of Thoracic Surgery, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy.

Massimiliano Mancini (M)

Division of Morphologic and Molecular Pathology Unit, S. Andrea Hospital, Rome, Italy.

Stefania Bellino (S)

National Center for Drug Research and Evaluation, National Institute of Health (ISS), Rome, Italy.

Elisa Giannetta (E)

Department of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy.

Mohsen Ibrahim (M)

Department of Thoracic Surgery, Sant'Andrea University Hospital, Rome, Italy.

Francesco Panzuto (F)

Digestive Disease Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Rome, Italy.
Department of Medical-Surgical Sciences and Translational Medicine, Sapienza University of Rome, Rome, Italy.

Maria Pia Brizzi (MP)

Department of Oncology, A.O.U. San Luigi Gonzaga Hospital, Orbassano, TO, Italy.

Antongiulio Faggiano (A)

Endocrinology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza University of Rome, ENETS Center of Excellence, Rome, Italy. antongiulio.faggiano@uniroma1.it.
ORCID: 0000-0002-9324-3946

Classifications MeSH